| Literature DB >> 24154874 |
Brandon Leonard1, Steven N Hart, Michael B Burns, Michael A Carpenter, Nuri A Temiz, Anurag Rathore, Rachel I Vogel, Jason B Nikas, Emily K Law, William L Brown, Ying Li, Yuji Zhang, Matthew J Maurer, Ann L Oberg, Julie M Cunningham, Viji Shridhar, Debra A Bell, Craig April, David Bentley, Marina Bibikova, R Keira Cheetham, Jian-Bing Fan, Russell Grocock, Sean Humphray, Zoya Kingsbury, John Peden, Jeremy Chien, Elizabeth M Swisher, Lynn C Hartmann, Kimberly R Kalli, Ellen L Goode, Hugues Sicotte, Scott H Kaufmann, Reuben S Harris.
Abstract
Ovarian cancer is a clinically and molecularly heterogeneous disease. The driving forces behind this variability are unknown. Here, we report wide variation in the expression of the DNA cytosine deaminase APOBEC3B, with elevated expression in the majority of ovarian cancer cell lines (three SDs above the mean of normal ovarian surface epithelial cells) and high-grade primary ovarian cancers. APOBEC3B is active in the nucleus of several ovarian cancer cell lines and elicits a biochemical preference for deamination of cytosines in 5'-TC dinucleotides. Importantly, examination of whole-genome sequence from 16 ovarian cancers reveals that APOBEC3B expression correlates with total mutation load as well as elevated levels of transversion mutations. In particular, high APOBEC3B expression correlates with C-to-A and C-to-G transversion mutations within 5'-TC dinucleotide motifs in early-stage high-grade serous ovarian cancer genomes, suggesting that APOBEC3B-catalyzed genomic uracil lesions are further processed by downstream DNA "repair" enzymes including error-prone translesion polymerases. These data identify a potential role for APOBEC3B in serous ovarian cancer genomic instability. ©2013 AACR.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24154874 PMCID: PMC3867573 DOI: 10.1158/0008-5472.CAN-13-1753
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701